U.S. FDA approves Eli Lilly’s drug for eczema
The United States Food and Drug Administration (FDA) has approved New England Council member Eli Lilly and Company’s eczema drug for use in adults and children above 12 years of age. The drug, an injectable medicine branded Ebglyss, will be available in the next few weeks, according to the company.
The FDA’s approval was based on three studies including over 1,000 patients with moderate-to-severe eczema who were unable to manage their symptoms with topical medicines or other systemic treatments, Eli Lilly said.
Unlike some other eczema drugs on the market, Ebglyss can be dosed once-monthly, which is “viewed as attractive by experts and likely also patients,” Jefferies analyst Lucy Codrington stated last year.
The New England Council commends Eli Lilly and Company for its efforts in creating new and innovative medicine to help improve the lives of patients.
Read more via Reuters.